RSS
8 Jan 2023

Jacobio Completes First Patient Dosage of Aurora A Inhibitor JAB-2485 in U.S

Author: admintech | Filed under: Press Release

BEIJING and SHANGHAI and BOSTON, Jan. 8, 2023 /PRNewswire/ — Jacobio Pharma (1167.HK) announced it has completed the first patient dosage of its in-house R&D drug candidate Aurora A Inhibitor JAB-2485 in a Phase I/IIa clinical trial for advanced solid tumour patients in U.S. JAB-2485 is…

This entry was posted on Sunday, January 8th, 2023 at 7:15 am and is filed under Press Release. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

«

»